1 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow RhGAA: new trials by email Literature Review of RhGAA trials Research Report on RhGAA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease VAL-1221, RhGAA - Pompe Disease | Phase 1 / Phase 2 | Terminated | Valerion Therapeutics, LLC | 12 | 2017-06-21 | 2020-06-02 |
| Drug-drug Interaction Study duvoglustat, rhGAA - Pompe Disease | Phase 2 | Completed | Amicus Therapeutics | 25 | 2011-10-31 | 2025-06-26 |
Glycogen Storage Disease Type II (2) · Glycogen Storage Disease (1)
Amicus Therapeutics (1) · Valerion Therapeutics, LLC (1)
United Kingdom (2) · United States (2) · Canada (1) · France (1)
Hal Landy, MD (1)